Lupin receives USFDA's approval for generic Gabapentin Tablets

28 Aug 2018 Evaluate

Lupin has received final approval for its Gabapentin Tablets USP, 600 mg and 800 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Pfizer Inc.'s Neurontin Tablets, 600 mg and 800 mg. Gabapentin Tablets USP, 600 mg and 800 mg had annual sales of around $180.7 million in the US as per IQVIA MAT June 2018.

Lupin's Gabapentin Tablets USP, 600 mg and 800 mg is the generic version of Pfizer's Neurontin Tablets, 600 mg and 800 mg. It is indicated for the treatment of postherpetic neuralgia in adults and adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2181.45 -9.05 (-0.41%)
09-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.95
Dr. Reddys Lab 1209.45
Cipla 1466.15
Zydus Lifesciences 894.95
Lupin 2181.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×